Unlocking the Fourth Great Wave in Cancer Treatment Post author:andrewkaretas Post published:November 8, 2023 Post category:Perspectives Continue ReadingUnlocking the Fourth Great Wave in Cancer Treatment
Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR Post author:andrewkaretas Post published:November 2, 2023 Post category:Dual/PLATFORM/Scientific Publications Continue ReadingPreclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR
Generation of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse Post author:andrewkaretas Post published:November 2, 2023 Post category:PLATFORM/Scientific Publications Continue ReadingGeneration of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse
Preclinical Development and Characterization of Allogeneic CAR T Cells Targeting Claudin18.2 Positive Tumors Post author:andrewkaretas Post published:November 2, 2023 Post category:CLAUDIN/Scientific Publications Continue ReadingPreclinical Development and Characterization of Allogeneic CAR T Cells Targeting Claudin18.2 Positive Tumors
Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models Post author:andrewkaretas Post published:August 23, 2023 Post category:BCMA/Scientific Publications Continue ReadingConstitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models
Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 15, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 13, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 12, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Presentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 9, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
The CAR T Revolution Continues: Progress Against Solid Tumors Post author:andrewkaretas Post published:May 2, 2023 Post category:Perspectives Continue ReadingThe CAR T Revolution Continues: Progress Against Solid Tumors
